Craig Rosenbaum | May 6, 2020 | Defective Drugs
The popular heartburn medication Zantac (ranitidine) was recalled and taken off shelves in September of 2019 after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in samples of Zantac. On February 6, 2020 the Judicial Panel for Multidistrict Litigation formed MDL No. 2924 in the federal court in… read more
Craig Rosenbaum | April 7, 2020 | Defective Drugs
New FDA Announcement Calls for Zantac to be Pulled from Market The popular heartburn medication Zantac (ranitidine) was recalled and taken off shelves in September of 2019 after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in samples of Zantac. The FDA has recently taken further action, announcing… read more
Craig Rosenbaum | February 20, 2020 | Defective Drugs
When officials revealed the possible existence of a dangerous carcinogen in Zantac, many longtime users of the heartburn drug took action. Lawsuits popped up across the country, all stemming from the worrying discovery of NDMA in the drug. Now, more than 140 of these federal lawsuits will be moving forward in a single court. Centralizing… read more
Craig Rosenbaum | January 15, 2020 | Defective Drugs
As of September of 2019, the popular heartburn medicine Zantac (ranitidine) has been recalled and taken off shelves in pharmacies after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in some batches of Zantac. Major pharmaceutical companies such as Sanofi-Aventis, Chattem, Inc., Boehringer Ingelheim, Pfizer, and GlaxoSmithKline have… read more
Craig Rosenbaum | December 10, 2019 | Defective Drugs
As of September of 2019, the popular heartburn medicine Zantac (ranitidine) has been recalled and taken off shelves in pharmacies after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in some batches of Zantac. Major pharmaceutical companies such as Sanofi-Aventis, Chattem, Inc., Boehringer Ingelheim, Pfizer, and GlaxoSmithKline have… read more
Rosenbaum Personal Injury Lawyers | November 20, 2019 | Defective Drugs, Products Liability
Zantac is one of the most popular heartburn medications in the United States. Millions of people use it frequently. That’s all due to change, as recent tests have revealed a cancer risk and major drugstores have started pulling the products. Here is what you need to know. Findings in September This is all very new,… read more
Craig Rosenbaum | November 1, 2019 | Defective Drugs
The U.S. Food and Drug Administration (FDA) publicly announced in September 2019 that dangerously high levels of the carcinogenic substance N-Nitrosodimethylamine (NDMA) have been found in the popular over-the-counter heartburn medication, Zantac. This means that millions of people who have been taking Zantac have regularly been ingesting a chemical that is notorious for causing cancer…. read more
Craig Rosenbaum | August 28, 2018 | Defective Drugs, Defective Medical Devices, Products Liability
Following the continuous efforts by health advocates and thousands of women, Bayer announced that it will no longer sell its Essure birth control implant by the end of the year. The permanent birth control method resembles the spring of a ballpoint pen and does not require an incision or invasive surgery. The company says the… read more
Craig Rosenbaum | May 17, 2016 | Defective Drugs
Thousands of lawsuits are now being filed against the manufacturers of the blood thinner, Xarelto. These claims include that patients of Xarelto, have suffered serious injuries and even death as a product of taking the anti-coagulant drug. Specifically, they allege that the side effects of Xarelto include excessive and most importantly, uncontrollable bleeding which they… read more
Craig Rosenbaum | March 18, 2016 | Defective Drugs
The defective drug, Xarelto, a blood thinner and anticoagulant drug manufactured to treat and prevent blood clots is now the source of thousands of lawsuits commenced against the drug’s developers, Johnson & Johnson and Bayer. The US Food and Drug Administration approved Xarelto as a treatment for deep vein thrombosis, atrial fibrillation, and pulmonary embolism as well… read more